Gradon Nielsen, MD
Hematology & Oncology · Norfolk, VANPI 1669868774
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Array Biopharma Inc at 33.8% of the total. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 5 payments — averaging $88.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Array Biopharma Inc$150
- Astellas Pharma US Inc$100
- AbbVie$95
- Daiichi Sankyo Inc.$79
- Incyte Corporation$20
What the payments were for
- Speaking & faculty fees$15034%
- Food & beverage$9922%
- Education$19544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Array Biopharma Inc | 1 | $150 |
| Astellas Pharma US Inc | 1 | $100 |
| AbbVie | 1 | $95 |
| Daiichi Sankyo Inc. | 1 | $79 |
| Incyte Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$444 in reported general payments places this provider in the 30th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 36 | $422,802 |
| CabometyxCabozantinib S-Malate | 13 | $316,749 |
| AlecensaAlectinib Hcl | 12 | $219,464 |
| CalquenceAcalabrutinib Maleate | 11 | $169,632 |
| NubeqaDarolutamide | 12 | $144,062 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $111,022 |
| EliquisApixaban | 54 | $48,211 |
| XareltoRivaroxaban | 23 | $24,698 |
| Anagrelide Hcl | 19 | $2,323 |
| Ondansetron Hcl | 53 | $1,127 |
| Dexamethasone | 73 | $748 |
| Doxycycline Hyclate | 12 | $439 |
| Acyclovir | 34 | $435 |
| Letrozole | 27 | $404 |
| Hydroxyurea | 16 | $374 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Norfolk
- Gary SimmonsNorfolk$82K
- Michael DansoNorfolk$47K
- Nina BalanchivadzeNorfolk$16K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.